nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC6A3—attention deficit hyperactivity disorder	0.81	1	CbGaD
Lisdexamfetamine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.0169	0.29	CbGeAlD
Lisdexamfetamine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00899	0.154	CbGeAlD
Lisdexamfetamine—SLC6A3—Clearance of dopamine—COMT—attention deficit hyperactivity disorder	0.0063	0.0504	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Clearance of dopamine—MAOA—attention deficit hyperactivity disorder	0.00626	0.05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.00545	0.0436	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—forebrain—attention deficit hyperactivity disorder	0.00343	0.0589	CbGeAlD
Lisdexamfetamine—SLC18A2—Dopamine Neurotransmitter Release Cycle—SNAP25—attention deficit hyperactivity disorder	0.00333	0.0266	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Norepinephrine Neurotransmitter Release Cycle—SNAP25—attention deficit hyperactivity disorder	0.00333	0.0266	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA4—attention deficit hyperactivity disorder	0.00316	0.0253	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—attention deficit hyperactivity disorder	0.00288	0.023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.00286	0.0229	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—attention deficit hyperactivity disorder	0.00285	0.0228	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD3—attention deficit hyperactivity disorder	0.00285	0.0228	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—attention deficit hyperactivity disorder	0.00284	0.0227	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD4—attention deficit hyperactivity disorder	0.00276	0.0221	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—STUB1—attention deficit hyperactivity disorder	0.00271	0.0217	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.0026	0.0446	CbGeAlD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD2—attention deficit hyperactivity disorder	0.00258	0.0206	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Norepinephrine Neurotransmitter Release Cycle—MAOA—attention deficit hyperactivity disorder	0.0025	0.02	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—midbrain—attention deficit hyperactivity disorder	0.00227	0.0389	CbGeAlD
Lisdexamfetamine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.0021	0.036	CbGeAlD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC6A3—attention deficit hyperactivity disorder	0.00197	0.0158	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—SLC6A3—attention deficit hyperactivity disorder	0.00197	0.0158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.00193	0.0154	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—attention deficit hyperactivity disorder	0.00191	0.0153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.00189	0.0151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.00188	0.0323	CbGeAlD
Lisdexamfetamine—SLC18A2—nervous system—attention deficit hyperactivity disorder	0.00186	0.032	CbGeAlD
Lisdexamfetamine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.00181	0.0311	CbGeAlD
Lisdexamfetamine—SLC18A2—central nervous system—attention deficit hyperactivity disorder	0.00179	0.0308	CbGeAlD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.00177	0.0141	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—cerebellum—attention deficit hyperactivity disorder	0.00175	0.0301	CbGeAlD
Lisdexamfetamine—SLC6A2—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00174	0.0139	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.00172	0.0294	CbGeAlD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—SNAP25—attention deficit hyperactivity disorder	0.00169	0.0135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.00162	0.013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.00159	0.0127	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.00157	0.0125	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00154	0.0123	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—SLC6A4—attention deficit hyperactivity disorder	0.00145	0.0116	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—SNAP25—attention deficit hyperactivity disorder	0.00145	0.0116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—brain—attention deficit hyperactivity disorder	0.00144	0.0247	CbGeAlD
Lisdexamfetamine—SLC18A2—brain—attention deficit hyperactivity disorder	0.00142	0.0245	CbGeAlD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.00141	0.0113	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.00141	0.0242	CbGeAlD
Lisdexamfetamine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.00136	0.0233	CbGeAlD
Lisdexamfetamine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.00133	0.0228	CbGeAlD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC6A3—attention deficit hyperactivity disorder	0.00133	0.0106	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—MAOA—attention deficit hyperactivity disorder	0.00127	0.0102	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.00126	0.0101	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.00125	0.01	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00118	0.00947	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.00114	0.00915	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.00114	0.0195	CbGeAlD
Lisdexamfetamine—Methamphetamine—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.176	CrCbGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0011	0.0088	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.0011	0.0188	CbGeAlD
Lisdexamfetamine—SLC6A3—brain—attention deficit hyperactivity disorder	0.00108	0.0185	CbGeAlD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00106	0.0085	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.00103	0.00824	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00101	0.0081	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00101	0.00805	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.001	0.008	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.000962	0.00769	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.000931	0.00745	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.000907	0.00726	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.000894	0.00715	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—brain—attention deficit hyperactivity disorder	0.000869	0.0149	CbGeAlD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.000866	0.00692	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.000851	0.00681	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000841	0.00672	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000783	0.00626	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000771	0.00616	CbGpPWpGaD
Lisdexamfetamine—Selegiline—MAOA—attention deficit hyperactivity disorder	0.000736	0.115	CrCbGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.000706	0.00564	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.000677	0.00541	CbGpPWpGaD
Lisdexamfetamine—Dextroamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000654	0.103	CrCbGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000652	0.00522	CbGpPWpGaD
Lisdexamfetamine—Phenelzine—MAOA—attention deficit hyperactivity disorder	0.000648	0.102	CrCbGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000606	0.00485	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.0006	0.0048	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—MAOA—attention deficit hyperactivity disorder	0.000566	0.0889	CrCbGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000548	0.00439	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.000541	0.00432	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000527	0.0827	CrCbGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000521	0.00417	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000519	0.00415	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000511	0.00409	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000488	0.0767	CrCbGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000488	0.0039	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000485	0.00388	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—ADRA2A—attention deficit hyperactivity disorder	0.000479	0.0751	CrCbGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000464	0.00371	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000432	0.00345	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.000419	0.00335	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000399	0.00319	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—SLC6A4—attention deficit hyperactivity disorder	0.000394	0.0619	CrCbGaD
Lisdexamfetamine—Amphetamine—DRD2—attention deficit hyperactivity disorder	0.000392	0.0615	CrCbGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000374	0.00299	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000372	0.00297	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.000372	0.00297	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000371	0.00297	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000367	0.00294	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—SLC6A4—attention deficit hyperactivity disorder	0.000365	0.0573	CrCbGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000365	0.00292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000364	0.00291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.000364	0.00291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000362	0.00289	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000361	0.00289	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00035	0.0028	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000344	0.00275	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000331	0.00265	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000328	0.00262	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000319	0.00255	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000312	0.0025	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000311	0.00248	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000305	0.00244	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000291	0.00233	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000289	0.00231	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000281	0.00225	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000279	0.00223	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000277	0.00221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000253	0.00202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000243	0.00194	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000238	0.0019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000238	0.0019	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000236	0.00188	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000221	0.00177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000221	0.00177	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000219	0.00175	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000217	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000216	0.00173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000205	0.00164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000204	0.00164	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000199	0.00159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000195	0.00156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000193	0.00154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000189	0.00151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000186	0.00148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00018	0.00144	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000178	0.00142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000176	0.00141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00017	0.00136	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000168	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000167	0.00134	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000167	0.00133	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000165	0.00132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000165	0.00132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000163	0.0013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000154	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000146	0.00116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000144	0.00115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000137	0.0011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000134	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000134	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00013	0.00104	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000127	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000126	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000126	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000125	0.000996	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000122	0.000976	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00012	0.000957	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000117	0.000938	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00011	0.000877	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000108	0.000863	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	9.31e-05	0.000745	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	8.56e-05	0.000685	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	8.46e-05	0.000676	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	8.21e-05	0.000657	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	8.14e-05	0.000651	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	7.57e-05	0.000605	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	7.39e-05	0.000591	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	7.36e-05	0.000588	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	7.33e-05	0.000586	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	7.21e-05	0.000576	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	7.2e-05	0.000576	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	7.11e-05	0.000569	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	7.07e-05	0.000565	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	6.87e-05	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	6.66e-05	0.000532	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	6.63e-05	0.00053	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	6.54e-05	0.000523	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	6.46e-05	0.000517	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.02e-05	0.000481	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5e-05	0.000399	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.64e-05	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.37e-05	0.000349	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.22e-05	0.000337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.06e-05	0.000325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.93e-05	0.000314	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.86e-05	0.000309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.82e-05	0.000305	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.56e-05	0.000284	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.49e-05	0.000199	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.32e-05	0.000106	CbGpPWpGaD
